相達生物科技任命雅培前高管殷鹏博士為首席科學官，推動科學創新和全球研發戰略

Hong Kong — 9 May 2025 — PHASE Scientific, a high-growth innovator in diagnostic technologies, is pleased to announce the appointment of Dr. Yin Peng as Chief Scientific Officer (CSO), effective immediately. Dr. Yin will be responsible for leading the company’s global Research & Development (R&D), clinical strategy, and scientific innovation roadmap.
 

As CSO, Dr. Yin will spearhead the strategic development and integration of PHASE’s proprietary PHASIFY™ technology platform, guiding its application across product development, clinical collaborations, and market-driven innovation. He will strengthen partnerships and accelerate the translation of breakthrough technologies into scalable, commercial-ready solutions.
 

“We are thrilled to welcome Dr. Yin Peng to the Phase leadership team,” said Dr. Ricky Chiu, CEO and Chairman of PHASE. “With his deep scientific expertise, global experience, and visionary leadership, Dr. Yin will play a critical role in driving our next phase of growth and solidifying our position as a key innovator in diagnostics.”
 

Dr. Yin brings over 25 years of international leadership experience in the diagnostics and biotechnology sectors. He spent 18 years at Abbott Diagnostics, where he held senior roles across R&D, scientific, and medical affairs functions at both regional and global levels. Most recently, he served as Chief Technology Officer at Sansure Biotech, a listed and a leading Chinese diagnostics company.
 

Dr. Yin began his career as an abdominal surgeon after earning his M.D. from Tianjin Medical School, later transitioning to research with a Ph.D. in Molecular Virology from the University of Manitoba and a postdoctoral fellowship at Harvard University. He is also a Fellow of the National Academy of Clinical Biochemistry and actively contributes to several professional organizations advancing clinical diagnostics worldwide.